Guided Therapeutics, Inc. Continues to Await Update From FDA on Its PMA Application for LuViva® Advanced Cervical Scan
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today commented on the status of its Pre-market Approval (PMA) application for the LuViva® Advanced Cervical Scan. While the Company requested a phone meeting with the U.S. Food and Drug Administration (FDA) after the passing of their 180 day internal guidance and did speak with the agency, the company was informed that LuViva remains under FDA review.
Help employers find you! Check out all the jobs and post your resume.
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today commented on the status of its Pre-market Approval (PMA) application for the LuViva® Advanced Cervical Scan. While the Company requested a phone meeting with the U.S. Food and Drug Administration (FDA) after the passing of their 180 day internal guidance and did speak with the agency, the company was informed that LuViva remains under FDA review.
Help employers find you! Check out all the jobs and post your resume.